Patrick B. Johnston

Orthopedics

705 Marketplace Plaza
Suite 100
Steamboat Springs, CO 80487

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 161 publications

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 27, 2026

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study.

Neurotoxicity in older patients with relapsed or refractory large B-cell lymphoma treated with CAR T-cell therapy: A multicenter study.

Journal: Transplantation and cellular therapy

Published: January 29, 2026

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances

Published: December 08, 2025

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.

Journal: Blood advances

Published: December 08, 2025

Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.

Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.

Journal: Blood cancer journal

Published: October 03, 2025

Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort Study.

Comprehensive Analysis of Subtype-Specific Outcomes and Management in Castleman Disease: A 20-Year Cohort Study.

Journal: Blood advances

Published: September 08, 2025

Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.

Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.

Journal: Blood advances

Published: September 08, 2025

Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).

Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).

Journal: Hematological oncology

Published: September 08, 2025

The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma.

The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma.

Journal: Blood cancer journal

Published: August 18, 2025

Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.

Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.

Journal: British journal of haematology

Published: July 16, 2025

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 07, 2025

Showing 1-12 of 161

Last Updated: 09/26/2026